NCT05933525Phase 2Completed

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

Study sponsor: Immuron Ltd. · IMRN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2024-07-01Actual
Enrollment · participants63Actual
Source updated2026-06-12Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.

+ After

Measure: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To measure the protective efficacy of oral administration of Travelan compared to placebo against moderate-to-severe diarrhea following with E.coli (ETEC) challenge.

+ After

Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.

Actual enrollment increased by 3 participants

− Before

60 participants (actual)

+ After

63 participants (actual)

Check registry source